Axplora announces the appointment of its Scientific Advisory Board

Axplora, a leading partner to Pharma companies and Biotechs for complex APIs, is pleased to introduce its Scientific Advisory Board, reflecting the innovation mindset embedded in its origins as Farmabios, Novasep and PharmaZell. The SAB provides insight and guidance to the Research & Development organization, supporting them to develop and offer innovative offerings meeting customer’s and patient’s needs. 

Dr. David Cantillo is a group leader and senior lecturer at the University of Queensland. He is an eminent researcher with expertise in flow chemistry, electrochemistry and photochemistry. 

Prof. Alois Fürstner is currently Director at the Max-Planck-Institute für Kohlenforschung, Mülheim/Ruhr, Germany, an elite institution in the area of catalysis research for more than a century. He is renowned for his expertise in homogeneous catalysis, organometallic chemistry, and target-oriented synthesis. 

Prof. Kerry Chester is Professor of Molecular Medicine at UCL, a top global university, and she is on the Board of Directors of The Antibody Society. Kerry’s group created and manufactured the first single chain Fv antibody (scFv) to enter clinical trials and she has over 30 years’ experience in development of antibody-based therapeutics. 

Prof. John Woodley is Professor of Chemical Engineering in the Department of Chemical and Biochemical Engineering at the Technical University of Denmark. He is an expert in biochemical engineering and biocatalysis, and has collaborated with many universities and industrial players. 

Axplora Group GmbH Hochstrass-Süd 7 83064 Raubling Germany 

Dr. Michael Reschke is Director / Consultant at Reschke Technology Consulting. He has more than 30 years’ experience in steroids and bile acids and has expertise in large-scale fermentation of steroid intermediates. 

“The DNA of our company includes technology, thinking differently and being more innovative”, says Dr. Sylke Hassel, Chief Executive Officer of Axplora. “The Scientific Advisory Board aims to support and challenge our sizeable R&D team for even more innovation, with a customer-oriented mindset. Innovation is the engine to meet customer’s expectations for the benefit of their patients.” 




“We embrace a culture of exploration, collaborating closely with universities, research centers, and start-ups”, adds Dr. Ester Masllorens, Chief Technology Officer of Axplora “Thanks to leading international and complementary experts in their respective areas, our Scientific Advisory Board strengthens the deployment of innovative and sustainable technologies and modalities, enabling us consistently to look out for new elements in the value chain that could transform the way pharmaceutical players bring their drugs to market.” 

The SAB works with R&D teams in the field to assess innovation projects and direction, and shares their research to position Axplora as an innovative and scientific leader.